KALA News and Press, Kala Pharmaceuticals Inc. From 08/11/22

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kala Pharmaceuticals (KALA) Investor Presentation (Slideshow)

Shares of micro-cap clinical-stage biopharmaceutical company Kala Pharmaceuticals ( NASDAQ: KALA ) gained as much as 23.6% to $0.43 after it said it expects significantly reduced operating expenses going forward and extended its anticipated cash runway. KALA stock had pa...

Kala Pharmaceuticals press release ( NASDAQ: KALA ): Q2 GAAP EPS of -$0.38. Revenue of $2.1M (-31.1% Y/Y). As of June 30, 2022, Kala had cash, cash equivalents and short-term investments of $44.6M, compared to $92.1M of cash and cash equivalents as of December 31, 2021...

-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, E...

Kala Pharmaceuticals ( NASDAQ: KALA ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.36 (+36.8% Y/Y) and the consensus Revenue Estimate is $2.02M (-33.8% Y/Y). Over the last 3 months, EPS est...

Major earnings expected before the bell on Thursday include: Arrival ( ARVL ) Brookfield Asset Management ( BAM ) Cardinal Health ( CAH ) Hanesbrands ( HBI ) Himax Technologies ( HIMX ) For further details see: Notable earnings before Thur...

ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report sec...

ARLINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that management will pa...

ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, announced today that it has completed th...

Today, we take our first look at ocular focused biotech IVERIC bio, Inc. The stock has seen some insider buying here in June and its primary asset Zumira seems on the path to commercialization. An investment analysis follows in the paragraphs below. For further details see: ...